Share This Article:

Viral Characteristic of HIV Infected Patients Naïf of Anti-Retroviral Therapy with CD4+ T Lymphocytes Rate Greater than 350 per Microliter of Blood in Lomé Togo

Abstract Full-Text HTML Download Download as PDF (Size:122KB) PP. 364-366
DOI: 10.4236/wja.2013.34047    2,185 Downloads   3,160 Views   Citations

ABSTRACT

Objective: To evaluate the virological status of ineligible HIV patients for anti-retroviral therapy based on the criterion of CD4+ T lymphocytes rate over than 350/μl of blood. Method: This is a prospective study which was conducted from November 2011 to July 2012 in the tropical and infectious disease department of CHU Sylvanus Olympio of Lomé. All HIV-1 infected patients whose CD4+ T lymphocytes rate was ≥350/μl of blood were retained. The count of CD4+ T lymphocytes was made by cytometer FACSCalibur? flow of BD biosciences and the determination of viral load was achieved by NASBA laboratory method of Biomérieux. Results: We have recruited 102 PLWHA aged between 19 and 58 years with a median of 35 years. Biologically, 102 patients had a T-CD4 rate between 355 and 432/μl of blood. The determination of viral load showed a very high viral replication more than 10,000 copies/ml among all patients and 28 (27.5%) patients had a viral load > 100,000 copies/ml of blood. Conclusion: Our results argue for a reconsideration of the criteria for starting antiretroviral therapy in Togo by including virological data if necessary in patients with T-CD4 rate below 500/μl of blood.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

I. Wateba, A. Patassi, A. Balaka and O. Tidjani, "Viral Characteristic of HIV Infected Patients Naïf of Anti-Retroviral Therapy with CD4+ T Lymphocytes Rate Greater than 350 per Microliter of Blood in Lomé Togo," World Journal of AIDS, Vol. 3 No. 4, 2013, pp. 364-366. doi: 10.4236/wja.2013.34047.

References

[1] PNLS-INFO No. 001/2007 PNLS-Togo, 2007, 1-5.
[2] PNLS, “Directives Pour une Prise en Charge Avec les Médicaments Antirétroviraux (ARV) au Togo,” 2004, pp 3-9.
[3] PNLS, “Guide National de la Prise en Charge Médiacle du VIH/SIDA: Affections Opportunistes et Traitement par les Antirétroviraux,” 2004, p. 104.
[4] OMS, “Recommendation Pour une Approche de Santé Publique: Améliorer L’accès aux Traitements Antirétroviraux dans les Pays à Ressources Limitées,” 2002, pp. 8-9.
[5] ONUSIDA, “Rapport sur l’épidémie Mondiale de SIDA,” ONUSIDA, Genève, 2006, pp. 3-4.
[6] R. D. Moore and J. C. Keruly, “CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Person with Sustained Virologic Suppression,” Clinical Infectious Diseases, Vol. 44, No. 3, 2007, pp. 441-446. http://dx.doi.org/10.1086/510746
[7] J. V. Baker, G. Peng, J. Rapkin, et al., “CD4+ Count and Risk of Non-AIDS Diseases Following Initial Treatment for HIV Infection,” AIDS, Vol. 22, No. 7, 2008, pp. 841-888.
http://dx.doi.org/10.1097/QAD.0b013e3282f7cb76
[8] S. Emery, J. A. Neuhaus, A. N. Phillips, et al., “Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study,” Journal of Infectious Diseases, Vol. 197, No. 8, 2008, pp. 1133-1144.
http://dx.doi.org/10.1086/586713
[9] HIV-CAUSAL Collaboration, et al., “The Effect of Combined Antiretroviral Therapy on the Overall Mortality of HIV-Infected Individuals,” AIDS, Vol. 24, No. 1, 2010, pp. 123-137.
http://dx.doi.org/10.1097/QAD.0b013e3283324283
[10] M. Guiguet, F. Boue, J. Cadranel, J. M. Lang, E. Rosenthal and D. Costagliola, “Effect of Immunodeficiency, HIV Viral Load, and Antiretroviral Therapy on the Risk of Individual Malignancies (FHDH-ANRS CO4): A Prospective Cohort Study,” Lancet Oncology, Vol. 10, No. 12, 2009, pp. 1152-1159.
http://dx.doi.org/10.1016/S1470-2045(09)70282-7
[11] C. F. Kelley, C. M. Kitchen, P. W. Hunt, et al., “Incomplete Peripheral CD4+ Cell Count Restoration in HIV Infected Patients Receiving Long-Term Antiretroviral Treatment,” Clinical Infectious Diseases, Vol. 48, No. 6, 2009, pp. 787-794. http://dx.doi.org/10.1086/597093
[12] M. Egger, M. May, G. Chêne, et al., “Prognosis of HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy: A Collaborative Analysis of Prospective Studies,” Lancet, Vol. 360, No. 9327, 2002, pp. 119-129.
http://dx.doi.org/10.1016/S0140-6736(02)09411-4
[13] J. P. Phair, J. W. Mellors, R. Detels, J. B. Margolick and A. Munoz, “Virologic and Immunologic Values Allowing Safe Deferral of Antiretroviral Therapy,” AIDS, Vol. 16, No. 18, 2002, pp. 2455-2459.
http://dx.doi.org/10.1097/00002030-200212060-00011
[14] E. Wood, R. S. Hogg, B. Yip, et al., “Higher Baseline Levels of Plasma Human Immunodeficiency Virus Type 1 RNA Are Associated with Increased Mortality after Initiation of Triple-Drug Antiretroviral Therapy,” Journal of Infectious Diseases, Vol. 188, No. 10, 2003, pp. 1421-1425.
http://dx.doi.org/10.1086/379201
[15] Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, et al., “Response to Combination Antiretroviral Therapy: Variation by Age,” AIDS, Vol. 22, No. 12, 2008, pp. 1463-1473.
http://dx.doi.org/10.1097/QAD.0b013e3282f88d02
[16] A. H. Greenbaum, L. E. Wilson, J. C. Keruly, R. D. Moore and K. A. Gebo, “Effect of Age and HAART Regimen on Clinical Response in an Urban Cohort of HIV-Infected Individuals,” AIDS, Vol. 22, No. 17, 2008, pp. 2331-2339.
http://dx.doi.org/10.1097/QAD.0b013e32831883f9

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.